Askgrabber Posted - 6 hours ago

$AMLX 👀

Fighting_ALS Posted - 14 hours ago

$AMLX Anyone?

campb029 Posted - 2 days ago

$AMLX followed this stock yrs ago after the adcom approval. What happened earlier this yr causing the drop? Thinking about taking a flyer on it at this level.

Greenenergy33 Posted - 2 days ago

$AMLX CEO should.....

FredDurst Posted - 1 week ago

$AMLX took half a position this AM

buttface696969 Posted - 1 week ago

$AMLX If it hits below $1.78 I'll buy more.

Dboy4realz Posted - 1 week ago

$AMLX $1.6s I called it

Fighting_ALS Posted - 1 week ago

$AMLX When do they plan to release more data from the Phoenix trial?

TM555 Posted - 1 week ago

$AMLX in here for a look.

dan_xdx Posted - 1 week ago

$AMLX It should close the gap

biostock Posted - 1 week ago

$CRBU $GOSS $CHRS $AMLX $ETNB Keep on the watchlist

thres Posted - 1 week ago

$BCLI By Comparison $AMLX Revenues 2023 380M$ for a food supplement that got cancelled in April 2024. We all know Nurown Works and Nurown is the real thing. So we can expect sales in a similar range 380M$ first year and and people can no longer ingest AMLX due to severe gagging and diarrhea which is serious impediment for ALS patients. With Nurown less attrition, no cancellation due to severe gagging and diarrhea causing discomfort hence a steady flow of repeat customers, new ALS patients all the time, international markets impatient to get Nurown in bodies. Sales could double the 2nd full year 750M$ or better and then keep on keeping on. Nurown is the best ALS meds in 155 years, Nurown Phase 3 responders and EAP ALS patients know Nurown works. Go Nurown, knock the ball out of the park!!!

zrosiez Posted - 1 week ago

$AMLX looks like they could pump

GOLDEN_PLATINUM_NEEDLE Posted - 1 week ago

$AMLX this will be a $7.00 - $9.09 stock within the next 12 months. Mark it.

iSmith Posted - 2 weeks ago

$AMLX Valuation Measures: Market Cap (intraday) 155.05M Enterprise Value -214.55M Total Cash 373.29M Total Cash Per Share 5.49 Total Debt 3.69M

Hassan77 Posted - 2 weeks ago

$AMLX Was hoping we would continue the positive momentum but it looks like a slight pull back before we potentially head to $3 and beyond.

stockregion Posted - 2 weeks ago

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist Avexitide. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delves into the details of the acquisition, the scientific background of avexitide, and the future plans for its development and clinical trials. $AMLX https://stockregion.app/p/pharmaceuticals-company-announces-caf

StockElementCorporation Posted - 2 weeks ago

$ADBE - Piper Sandler lowers Adobe price target to $635 from $700, Overweight rating - $AMLX - Goldman Sachs raises Amylyx Pharmaceuticals price target to. $4 from $3, Neutral rating - $AMP - Piper Sandler cuts Amplitude price target to $9 from $11, Neutral rating

biostock Posted - 2 weeks ago

$AMLX $GOSS $CHRS $CRBU small caps keep on radar for bigger move as tutes and whales returns to $IWM to remove their short hedges.

DiamondMarket Posted - 2 weeks ago

$AMLX Still uptrending nicely 💸

ajmore Posted - 2 weeks ago

$AMLX targets going up!

AnaChart Posted - 2 weeks ago

$AMLX https://anachart.com/wp-content/uploads/ana_temp/1720782077_soc-img.jpg

Yassaom Posted - 2 weeks ago

$AMLX wake up every one , its party day!!!🚀

Hassan77 Posted - 2 weeks ago

$AMLX Great day bulls! lets do it again tomorrow shall we?

buttface696969 Posted - 2 weeks ago

@Moell it's a REQUIREMENT for pharma biotechs to have huge cash reserves in case shit hits the fan, and for $AMLX it happened in March.

DonCorleone77 Posted - 2 weeks ago

$AMLX Amylyx price target raised to $4 from $3 at Goldman Sachs Goldman Sachs raised the firm's price target on Amylyx to $4 from $3 and keeps a Neutral rating on the shares. The firm cites the company's acquisition of Phase 3-ready avexitide from Eiger as announced yesterday and contends that the deal for a "relatively de-risked" asset builds Amylyx's late-stage pipeline, even though much remains to be understood regarding the market opportunity, including in the context of GLP-1RAs and other anti-obesity medications which may disrupt the rate of bariatric surgeries over the medium to long-term, the analyst tells investors in a research note.

sellhigh69 Posted - 2 weeks ago

$AMLX giddy up finally boys

mojo999 Posted - 2 weeks ago

$AMLX $2.22 Float 46M Short 4.6M=9.94% $5 PER SHARE NET CASH & TRANSFORMATIONAL GLP-1 DRUG ACQUISITION MATERIAL SHORT-TERM RE-VALUATION OPPORTUNITY. NEW DRUG ACQUISITION AVEXITIDE ⭐Bought out of Texas bankruptcy court from Eiger Biopharmaceuticals for just $35M cash +5M cash +3% revenue royalty in PBH indication. ⭐Novel GLP-1 receptor antagonist with the potential to treat multiple diseases associated with hyperinsulinemic hypoglycemia. ⭐Targets known GLP-1 receptor but with a novel mechanism so it has “first in class” potential (can lead to expedited approvals, leading competitive positions…) ⭐Highly statistically significant & clinically meaningful data (dose escalation & p-values from 0.004 to 0.0003) to date in 2 chronic & progressive hyperinsulinemic hypoglycemia indications: PBH & congenital HI. ⭐FDA Break-through therapy designations given for both indications. Both are significant... READ MORE & FOLLOW HERE FOR UPDATES: https://x.com/smantel/status/1811498220687884685

Hassan77 Posted - 2 weeks ago

$AMLX I hope they release another banger PR piece that makes it go parabolic tomorrow morning